title: Lower-dose efavirenz: what is needed before implementation?
authors: Division of Clinical Pharmacology (GaM) and Division of Infectious Diseases and HIV Medicine, Department of Medicine, University of Cape Town, Cape Town, South Africa.
authors: Gary
authors: G
authors: Maartens
authors: Clinical Infectious Diseases Research Initiative, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road, Cape Town, 7925, South Africa. Electronic address: graemein@mweb.co.za.
authors: Graeme
authors: G
authors: Meintjes
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D048588:Benzoxazines / Q000008:administration & dosage* / Q000009:adverse effects*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D008297:Male; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*
chemical_list: D019380:Anti-HIV Agents; D048588:Benzoxazines; D018894:Reverse Transcriptase Inhibitors